Abstract:
The invention provides the LCB1 and LCB2 genes of the yeast Saccharomyces cerevisiae that encode subunits of the enzyme serine palmitoyltransferase (SPT), the first enzyme leading to synthesis of the long-base component of the sphingolipids. The present specification describes the isolation of the LCB1 and LCB2 genes. The invention further relates to methods of using these genes to either inhibit SPT activity or to inhibit synthesis of the enzyme. Furthermore, the invention relates to methods for constructing strains of S. cerevisiae or other organisms that can be used to select and to test for compounds that either inhibit SPT activity or to inhibit synthesis of the enzyme.

Description:
This application is a continuation of application Ser. No. 07/906,899 filed Jun. 30, 1992, now abandoned. 
    
    
     BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     This invention relates to the isolation of the LCB1 and LCB2 genes of the year Saccharomyces cervisiae that encode subunits of the enzyme serine palmitoyltransferase (SPT), the first enzyme leading to synthesis of the long-base component of sphingolipids. The invention further relates to method of using these genes to either inhibit SPT activity or to inhibit synthesis of the enzyme. Furthermore, the invention relates to methods for construction strains of S. cervisiae or other organisms that can be used to select and test for compounds that either inhibit SPT activity or to inhibit synthesis of the enzyme. 
     2. Description of the Background 
     Sphingolipids are abundant in the membranes of fungi (Brennah, P. J., &amp; Losel, D. M. 1978. Fungal lipids, in Microbial Physiology, Rose, A. H. &amp; Morris, P. G., Eds. 17, 47-179, Acad. Press., N.Y.), animals (Seeley, C. C. and Siddiqui, B. 1977; the Glycojungates, Horowitz, M. I. and Pigman, W., eds., Acad. Press, N.Y. 1:495), and higher plants (Laine, R. a., Hsieh, T. C.-Y., &amp; Lester, R. L. Glycophosphoceramides from plants, in Cell Surface Glycolipids, p.65, Am. Chem. Soc. Symp. Ser. 128, Am. Chem. Soc. Wash, D.C.) 1980. In spite of much effort, it has been difficult to understand the exact biological role(s) of sphingolipids and their mode of action at the molecular level. In animals, sphingolipids are thought to play a role in such general cellular events as cell-to-cell recognition, regulation of cell growth, and differentiation. The prevalence of sphingolipids suggests that they play vital roles in cells and direct proof that sphingolipids are essential cellular components has been obtained with the discovery of mutants of S. cervisiae that absolutely require a sphingolipid long-chain base (see below) for growth (Wells, G. B. and Lester, R. L.; J.Biol. Chem. 258: pages 10200-10203 (1983)) and viability (Pinto, W. J., Wells, G. B., Williams, A. C., Anderson, K. A., Teater, E. C., and Lester, R. L., Fed. Proc. 45: 1826 (1986)). 
     sphingolipids are derivatives of ceramides containing sugars and sometimes phosphates. Ceramides usually contain a fatty acid of 20-26 carbons connected via an amide linkage to a long-chain base. The major long-chain bases and their predominant distribution are: ##STR1## 
     Reaction (a), the first committed step in sphingolipid biosynthesis (reviewed in Merrill, A. H. and Jones, D. D. 1990. Biochemica et Biophysica Acta. 1044:1-12) is catalyzed by serine palmitoyltransferase (SPT, also called 3-ketodihydrosphingosine synthetase). This enzyme has been shown to occur in the fungus Hansenula ciferri (Snell, E. E., Di Mari, S. J., and Brady, R. N. 1970. Chem. Phys. Lipids, 5:116-138), in beef liver (Stoffel, W. 1970. Chem. Phys. Lipids. 5:139-158), and in the bacterium Bacteroides melaninogenicus (Lev, M., and Milford, A. F. 1973. Arch. Biochem. Biophys. 157:500-508). Other evidence for this reaction comes from our own work in S. cervisiae (Pinto et al., 1986; Pinto W. J., Wells, G. W. and Lester, R. L. 1992. J. Bacteriol. 174:2575-2581). The enzyme has never been purified to homogenity and characterized in any detail (reviewed in Merrill, A. H. and Jones, D. D. 1990. Biochemica et Biophysica Acta. 1044:1-12). 
     In reaction (d) the long-chain base is attached to a fatty acid to form a ceramide. In all organisms ceramides are converted to complex derivatives, the sphingolipids, by the addition of polar groups to the 1-hydroxyl. The sphingolipids in animals contain various oligosaccharides inked glycosidically to the ceramide to yield glycosphingolipids and also contain choline linked by a phosphodiester bond to ceramide to yield the abundant compound sphingomyelin. Certain sphingolipids in fungi and plants differ from the sphingolipids in animals because the 1-hydroxyl is linked through a phosphoryl group to inositol (myo-inositol) rather than directly to a sugar. This core structure, inositol-phosphorylceramide, or inositol-P-ceramide (&#34;IPC&#34;, Smith, S. W., and Lester, R. L. 1974. J. Biol. Chem. 249:3395-3405), along with mannose-inositol-P-ceramide, (MIPC, ibid) and mannose-(inositol-P) 2  -ceramide (M(IP) 2  C, (Steiner, S., Smith, S. Waechter, C. J., and Lester, R. L. 1969. Proc. Natl. Acad. Sci. U.S.A. 64:1042-1048) collectively constitute the sphingolipids in S. cervisiae (Smith, S. W., and Lester, R. L. 1974. J. Biol. Chem. 249:3395-3405). Phosphoinositol sphingolipids are also a major class of lipids in plants (for references see Kaul, K. and Lester, R. L. 1975. Plant Physiol., 55:120-129) and parasites (Singh, B. N., Costello, C. E., and Beach, D. H. 1991. Arch. Biochem. Biophys. 286:409-418). 
     Because sphingolipids are vital for S. cerevisiae, the long-chain base biosynthesis pathway would appear to be a good target for antifungal compounds. In fact, sphingolipids may be vital for all organisms that contain them, and therefore, any compound that would inhibit long-chain base biosynthesis might inhibit growth of an organism that contained sphingolipids. 
     Accordingly, there is a need to begin to identify or design such inhibitory antifungal compounds to target the long-chain base biosynthesis pathway, which would appear to be a good target for antifungal compounds. Therefore we isolated two S. cerevisiae genes, LCB1 (SEQ ID NOS.: 1-3) and LCB2 (SEQ ID NOS.: 4-6), that most likely encode subunits of SPT. These are the first genes involved in long-chain base biosynthesis to be isolated from any organism. The genes provide a unique opportunity to identify compounds that block SPT activity or synthesis in specific organisms. 
     SUMMARY OF THE INVENTION 
     One objective of the present invention is to provide the LCB1 (SEQ ID NOS.: 1-3), and the LCB2 ((SEQ ID NOS.: 4-6) genes of S. cerevisiae and to demonstrate that they provide SPT enzyme activity to a strain that lacks such enzyme activity. 
     Another objective of the present invention is to provide the LCB1 ((SEQ ID NOS.: 1-3), and the LCB2 ((SEQ ID NOS.: 4-6), genes of S. cerevisia for use in constructing a genetically engineered strain of S. cerevisiae that has increased SPT protein and therefore enzyme activity. 
     Another objective of the present invention is to provide the DNA sequence of the LCB1 ((SEQ ID NOS.: 1-3) and LCB2 ((SEQ ID NOS.: 4-6) genes for use as targets for antisense or triple-helix-forming oligonucleotides which will inhibit the production of SPT protein. 
     Another objective of the present invention is to provide the DNA sequence of the LCB1 (SEQ ID NOS.: 1-3) and LCB2(SEQ ID NOS.: 4-6) genes for use in overexpression of the genes and subsequent overproduction of the SPT enzyme. 
     Another objective of the present invention is to provide the DNA sequence of the LCB1 ((SEQ ID NOS.: 1-3) and LCB2 ((SEQ ID NOS.: 4-6) genes for use in isolating the homolog of these genes from other organisms. 
     Other objectives and advantages of the invention will become apparent as the description thereof proceeds. 
     In satisfaction of the foregoing objects and advantages, the present invention provides the LCB1 ((SEQ ID NOS.: 1-3) and LCB2 ((SEQ ID NOS.: 4-6) genes and their DNA sequence. The genes are shown to restore SPT activity to a lcb1((SEQ ID NOS.: 1-3)-defective and lcb2((SEQ ID NOS.: 4-6)-defective strain, respectively. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIG. 1 represents a schematic diagram of plasmids carrying the LCB1 (SEQ ID NOS.: 1-3) gene of S. cerevisiae. 
     FIG. 2 sets forth the DNA sequence of the LCB1 (SEQ ID NOS.: 4-6) gene and the predicted protein product. 
     FIG. 3 sets forth a comparison of the LCB1 (SEQ ID NOS.: 1-3) protein sequence with other proteins that catalyze a chemical reaction that is similar to the one catalyzed by SPT. 
     FIG. 4 sets forth a comparison of the reaction catalyzed by SPT and other enzymes. 
     FIG. 5(A-C) represents a schematic diagram of plasmids carrying the LCB2 (SEQ ID NOS.: 4-6) gene of S. cerevisiae or portions of the gene. 
     FIG. 6 sets forth the DNA sequence of the LCB2 (SEQ ID NOS.: 4-6) gene and the predicted protein sequence. 
     FIG. 7 sets forth a comparison of LCB1 (SEQ ID NOS.: 1-3), LCB2 (SEQ ID NOS.: 4-6), and the S. cerevisiae HEM1 protein sequences. 
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The invention relates to the isolation of the LCB1 (SEQ ID NOS.: 1-3) and LCB2 (SEQ ID NOS.: 4-6) genes of S. cerevisiae. 
     The present invention provides a DNA sequence LCB1 having a nucleotide sequence as set forth in FIG. 2. It also provides a plasmid comprising the LCB1 sequence according to the invention. Particularly preferred is a plasmid according to the invention which is the plasmid pTZ18-LCB1 (SEQ ID NOS.: 1-3) containing the LCB1 (SEQ ID NOS.: 1-3) sequence. Also, particularly preferred is a plasmid according to the invention which is plasmid YIpLCB1-1 containing the LCB1 sequence. 
     In another embodiment the present invention provides a host cell line transformed by a plasmid containing the LCB1 (SEQ ID NOS.: 1-3) sequence according to the present invention. 
     In another aspect the present invention provides a DNA sequence LCB2 (SEQ ID NOS.: 4-6) having a nucleotide sequence as set forth in FIG. 6. It also provides a plasmid comprising the LCB2 (SEQ ID NOS.: 4-6) sequence according to the invention. Particularly preferred is a plasmid according to the invention which is the plasmid pRSLCB2-2 containing the LCB2 (SEQ ID NOS.: 4-6) sequence. 
     In another embodiment the present invention provides a host cell line transformed by a plasmid containing the LCB2 (SEQ ID NOS.: 4-6) sequence according to the present invention. 
     The present invention further provides a genetically engineered strain of S. cerevisiae which has increased production of Serine Palmitoyltransferase protein and therefore increased enzyme activity as compared to the wild type S. cerevisiae. 
     In another aspect the present invention provides an antisense or triple helix forming oligonucleotide specific for the LCB1 (SEQ ID NOS.: 1-3) sequence, which will inhibit the production of Serine Palmitoyltransferase protein. 
     In still another aspect the present invention provides an antisense or triple-helic-forming oligonucleotide specific for the LCB2 (SEQ ID NOS.: 4-6) sequence, which will inhibit the production of Serine Palmitoyltransferase protein. 
     The present invention also provides a genetically engineered microbial strain transformed by a plasmid comprising either the LCB1 (SEQ ID NOS.: 1-3) or LCB2 (SEQ ID NOS.: 4-6) sequence, or both the LCB1 (SEQ ID NOS.: 1-3) and LCB2 (SEQ ID NOS.: 4-6) sequences, which overexpresses the gene(s) with which it is transformed and subsequently overproduces the Serine Palmitoyltransferase enzyme. 
     Also the present invention provides a method for testing an oligonucleotide or organic compound for the ability to block Serine Palmitoyltransferase activity or synthesis, which method comprises: 
     exposing the oligonucleotide or the organic compound being tested to a host cell or host cell extract, which host cell has been transformed to include either a LCB1 (SEQ ID NOS.: 1-3) gene or LCB2 (SEQ ID NOS.: 4-6) gene (or both genes), and 
     testing for an absence of Serine Palmitoyltransferase enzyme or its activity, which diminished activity is indicated by the absence or lower concentration of sphingolipids. 
     The present invention further provides an oligonucleotide DNA sequence, which is a complement to either the LCB1 (SEQ ID NOS.: 1-3) or LCB2 (SEQ ID NOS.: 4-6) sequences, or to portions thereof. 
     In yet another aspect the present invention provides a method of testing for and/or isolating closely related sequences (similar to LCB1 (SEQ ID NOS.: 1-3)) which comprises 
     producing or obtaining an oligonucleotide which is a complement to a portion of the LCB1 (SEQ ID NOS.: 1-3) gene, and 
     using the complement as an oligonucleotide probe by 
     exposing a target nucleotide sequence to the said nucleotide probe and testing for binding to said probe, and optionally 
     isolating and separating the nucleotide probe from the DNA sequence to which it has bound. 
     In still another aspect, the present invention provides a method of testing for and/or isolating closely related sequences (similar to LCB2 (SEQ ID NOS.: 4-6)) which comprises 
     producing or obtaining an oligonucleotide which is a complement to a portion of the LCB2 (SEQ ID NOS.: 4-6) gene, and 
     using the complement as an oligonucleotide probe by 
     exposing a target nucleotide sequence to the said nucleotide probe and testing for binding to said probe, and optionally 
     isolating and separating the nucleotide probe from the DNA sequence to which it has bound. 
     The LCB1 (SEQ ID NOS.: 1-3) and LCB2 (SEQ ID NOS.: 4-6) sequences according to the present invention, plasmids comprising either of the LCB1 (SEQ ID NOS.: 1-3) or LCB2 (SEQ ID NOS.: 4-6) sequences, transformed host cells having a sequence according to the present invention, and sequences which are complements are all useful in screening potential antifungal agents, or for producing reagents useful in screen potential antifungal agents, (both oligonucleotides and organic chemical agents, which are potential antifungal agents may be screened). 
     The sequences according to the present invention are also useful to provide oligonucleotides which have complementary DNA sequences, which complementary sequences can be used as probes to screen for sequences which are homologs of the claimed sequences and/or used in a process to isolate and ultimately sequence such homologs of LCB1 (SEQ ID NOS.: 1-3) or LCB2 (SEQ ID NOS.: 4-6). 
     In accordance with present invention, as a preliminary step, a mutant strain of S. cerevisiae blocked in sphingolipid biosynthesis was obtained. For example, strains of S. cerevisiae carrying the mutant allele, lcb1-1, are absolute auxotrophs and grow only when a long-chain base (lcb, phytosphingosine but not sphingosine) is added to the culture medium. 
     The genes were isolated from a S. cerevisiae genomic DNA library by complementation for growth on medium lacking a long-chain base (such as phytosphingosine) of an lcb1 or an lcb2-defective strain. 
     The original lcb mutant MCGA (MATα lcb1-1 inol (J. Biol. Chem. 258, 10200-10203 (1983) was crossed with strain W303-1B (MATα ade2-1 can1-100 ura3-1 his3-11,15 trp1-1 leu2-3,112; obtained from R. J. Rothstein, Columbia University). Progeny from this cross were backcrossed to W303-1B, and several offspring were selected for further study, including strains X2A1B (MATa lcb1-1 ura3-1 trp1-1 his3-11,15). Strain SL1 was derived from strain SJ21R (MATa ura3-52 leu2-3,112 ade1 MEL1) by replacement of the LCB1 allele with a mutant allele that was disrupted by inserting a 1.1-kb URA3 DNA fragment at the SalI site of LCB1. The LCB1:: URA3-disrupted allele was prepared by transferring 4.3-kb HindIII-StuI fragment, carrying LCB1, from pLCB to pTZ18 (Pharmacia) cleaved with HindIII and SmaI. The resulting plasmid, pTZ18-LCB1 was cleaved with SalI and ligated with a 1.1-kb URA3 DNA fragment having SalI cohesive ends (obtained from pUC-URA3 cut with SalI) to yield pTZ18-LCB1::URA3. 
     To replace the LCB1 chromosomal allele with the URA3-disrupted allele, 10 μg of pTZ18-LCB1::URA3 DNA was cleaved with XbaI and ClaI, extracted with phenol, phenol-chloroform, and chloroform and precipitated with ethanol. The DNA was transformed into strain SJ21R with selection for Ura+ transformants. Replacement of the LCB1 chromosomal allele with the URA3-disrupted allele was verified by Southern blot analysis. YIpLCB1-1 was constructed by inserting TRP1 of S. cerevisiae, as a 1.4-kb HindIII fragmentm into the HindIII site of pTZ18-LCB1. YIpLCB1-1 was cleaved at its unique BAMHI site located on the 3&#39;side of LCB1, and the linear DNA was used to transform strain 24D5 with selection for Ura+transformants. Integration at the expected chromosomal location was verified by Southern blotting. Transformants were crossed to strain YPH1 (MATa ura3-52 lys2-801 ade2-101 (See, for example, Genetics, 122, 19-27 (1989)). 
     The plasmid pLCB was isolated from a S. cerevisiae genomic DNA library carried in a CEN vector. The 6.44-kb vector was pBR322 with a 0.63-kb Sau3A CEN3 DNA fragment inserted into the PvuII site of the vector and a 1.4-kb TRTRP1 ARS1 fragment inserted into the EcoRI site of the vector. The ligations were done with molecules whose ends were made blunt ended so that the original restriction sites were destroyed. Sau3A genomic DNA fragments of 8-kb average size from strain X2180 (a/α gal2/gal2) were cloned into the BamHI site of the vector (the library was obtained from ZymoGenetics, Seattle, Wash.). DNA fragments from pLCB were subcloned into YCp50 (see, Methods Enzymol., 152, 481-504 (1987)). 
     Plasmids were propagated in Escherichia coli DH5α. The lcb-defective strains were propagated in several media as described later in the detailed section which follows. 
     For example, to isolate LCB1, strain X2A1B (relevant genotype lcb1-1, trp1) was transformed with a genomic DNA library which was carried in a vector containing CEN3 and ARS1, for single-copy propagation in yeast cells, and TRP1, for selection of Trp +  yeast that had been transformed with the vector. Ten thousand Trp +  transformants were selected on minimal medium plates containing phytosphingosine but lacking tryptophan. Transformants were pooled and reselected on minimal medium plates lacking both tryptophan and phytosphingosine. About one per thirty-five hundred Trp +  colonies was able to grow without added phytosphingosine and thus had an Lcb +  phenotype. 
     Plasmid DNA was isolated from several Lcb +  yeast transformants and transformed into E. coli with selection for ampicillin resistant cells. Plasmid DNA from E. coli transformants was isolated and digested with restriction endonucleases. The pattern of restriction fragments indicated that the original Lcb +  yeast transformants all contained the same plasmid which carried an insert of about 8 kb. 
     To localize the LCB1 gene on the 8 kb DNA insert we subcloned parts of the insert into the CEN4 vector YCp50 and tested the resulting plasmids for their ability to confer a Lcb +  phenotype on strain X2A1B. The experiments localized LCB1 to a subclone of 4.0 kb (FIG. 1). 
     Further localization of LCB1 was achieved by chromosomal disruption. For these experiments the 4 kb insert was disrupted at the unique SalI site (FIG. 1) by insertion of the URA3 gene of S. cerevisiae to create the lcb1::URA3-disruption allele. The lcb1::URA3-disruption allele was used to replace the wild type LCB1 allele in strain SJ21R (relevant phenotype Lcb +  Ura - ) by homologous recombination as described in EXAMPLE 2. These procedures produced a strain, SL1, having the chromosome disrupted at the expected SalI site. If this procedure had disrupted the LCB1 gene then the strain SL1should require long-chain base (phytosphingosine) for growth and, therefore, having an Lcb -  phenotype. This expectation was verified because strain SL1 had an Lcb -  phenotype. We conclude that the SalI site shown in plasmid YCp50-LCB1 between the PstI and HpaI sites is located within the LCB1 gene. 
     Genetic complementation analysis was used to verify that the lcb1::URA3 disruption mutation in strain SL1 was allelic to the original lcb1-1 mutation carried in strain X2A1B. Strain SL1 was crossed to strain 24D5. The resulting diploids had an Lcb -  phenotype, suggesting allelism of the cloned gene and lcb1. Strong support for allelism would be obtained by sporulating these diploids and showing that all tetrads give four Lcb -  spores. However, such diploids failed to sporulate under a variety of conditions suggesting that sphingolipids are needed for sporulation. An alternative genetic approach was used to demonstrate allelism. The putative LCB1 allele, carried on the integrating vector YIpLCB1-1, was directed to integrate into its homologous chromosomal locus as described in EXAMPLE 3. The host strain for integration of YIpLCB1 was strain 24D5 which carried the lcb1-1 mutation. If YIpLCB1-1 did indeed carry the wild type LCB1 gene then the host strain should have this plasmid integrated next to the lcb1-1 allele. When this strain is crossed to an LCB1 strain (YPH1) all progeny should be Lcb +  since YIpLCB1-1 should be tightly linked to lcb1-1 and there should be little if any recombination events that would separate the two alleles. In fourteen four-spored tetrads from such a cross, showing 2 +  :2 -  segregation for the Ade, Ura and Leu phenotypes, all spores were Lcb +  indicating that YIpLCB1 had been directed to integrate in close proximity to the lcb1-1 allele. We conclude that the LCB1 gene has been cloned and is carried on pTZ18-LCB1 gene as claimed. 
     To determine if SPT activity was missing in lcb1-defective strains and to determine if a plasmid carrying LCB1 restored such activity we assayed membranes for the enzyme. The parental strain MC6A contained 54.4 units of enzyme activity per mg of protein while the lcb1-defective strain X2A1B contained 2.5 units per mg of protein or about 20 times less enzyme activity that the parental strain: this level of activity is at the limit of detection and the actual enzyme activity may be lower. The cloned LCB1 allele carried in pLCB was able to restore enzyme activity to about 50% of the wild-type level since three independent transformants of strain X2A1B gave 22.7, 25.6, and 22.8 units of enzyme activity per mg of protein. These data support the claim that LCB1 encodes the SPT enzyme or a subunit of the enzyme. 
     Based upon the results of the lcb1::URA3 disruption experiments a region surrounding the SalI site shown in FIG. 1 was subjected to DNA sequence analysis and the sequence was analyzed by computer to locate large open reading frames which could encode the LCB1 protein. The sequence (FIG. 2) contained a single, large open reading frame, encoding 558 amino acids which was oriented in the same direction of transcription as the LCB1 mRNA (data not shown). This region must code for the LCB1 protein product because it is in the correct 5&#39; to 3&#39; orientation, because a URA3 disruption of the open reading frame at the unique SalI site created a Lcb -  phenotype, and because it is genetically tightly linked to the lcb1-1 allele. 
     The nucleotide sequence of the open reading frame was used to product the amino acid sequence of the LCB1 peptide. The results of the prediction are illustrated above each codon of the nucleotide sequence (FIG. 2) beginning with the first ATG codon at position +1 and ending with the stop codon TAA at position +1675. Assuming that this ATG codon is the true translation initiation site, the product of the open reading frame is a protein of 558 amino acids. Since the amino terminus of the LCB1 protein has not been determined directly it is possible that the amino terminus of the actual protein is different than indicated in FIG. 2. The difference could occur either because of post-translational processing or because an ATG codon down stream of the one shown in FIG. 3 is used as the initiation codon. 
     Because SPT activity is present in the membrane fraction of lysed cells, we expected the LCB1 protein to be membrane-associated. The hydrophobicity of the deduced protein sequence was therefore examined for potential membrane spanning regions. According to the 5theory of Kyte, J., and Doolittle, R. F. 1982. J. Mol. Biol. 157:105-132, the Grand Average Hydropathy Score (GRAVY) for the predicted LCB1 protein is -1.39, a value that places the protein in the same class as globular proteins. A globular, rather than integral membrane, protein is also predicted by the procedure of Eisenberg, D., Schwartz, E., Komaromy, M., and Wall, R. 1984. J. Mol. Biol. 179:125-142. In addition, this analysis predicts two very hydrophobic, membrane-associated helices. Helix I spans amino acid residues 12-32 and has the sequence IPIPAFIVTTSSYLWYYFNLV, while Helix II spans residues 344-373 and has the sequence ATAIDITVGSMATALGSTGGFVLG. 
     The predicted amino acid sequence of the LCB1 protein shows high similarity to the enzyme 5-aminolevulinic acid synthase (ALA synthase) whose structural gene has been sequenced from many organisms including S. cerevisiae (ALSY (SEQ ID NO.: 12), FIG. 3, Urban-Grimal, D., Wollard, C., Garnier, T., Dehoux, P., and Labbe-Boise, R. 1986. Eur. J. Biochem. 156:511-519), mouse (ALSM (SEQ ID NO.: 10), FIG. 3, Schoenhaut, D. S., and Curtis, P. J. 1986. Gene 48:55-63) and chicken (ALSC (SEQ ID NO.: 11), FIG. 3, Riddle, R. D., Yamamoto, M., and Engel, J. D. 1989. Proc. Natl. Acad. Sci. U.S.A. 86:792-796). The predicted LCB1 protein also shows high similarity to the Escherichia coli enzymes 2-amino-3-ketobutyrate CoA ligase (EKBL (SEQ ID NO.: 8), FIG. 3, Aronson, B. A., Ravnikar, P. D., and Somerville, R. L. 1988. Nucleic Acids Res. 16:3586) and biotin synthetase (EBIO, FIG. 3, Otsuka, A. J., Buoncristiani, M. R., Howard, P. K., Flamm, J., Johnson, C., Yamamoto, R., Uchida, K., Cook, C., Ruppet, J., and Matsuzaki, J. 1988. J. Biol. Chem. 263:19577-19585). 
     The similarity of the LCB1 protein to ALA synthase and to 2-amino-3-ketobutyrate CoA ligase seems particularly significant since these enzymes catalyze a reaction (FIG. 4) that is very similar to that catalyzed by SPT. In addition, the E. coli 2-amino-3-ketobutyrate CoA ligase uses pyridoxal phosphate as a cofactor (Mukherjee, J. J., Dekker, E. E. 1987. J. Biol. Chem. 262:14441-14447) as do serine palmitoyltransferase (Brady, R. O. and Koval, G. J. 1957. J. Am. Chem. Soc. 79:2648-2649) and ALA synthase (Warnich, G. R., and Burnham, B. F. 1971. J. Biol. Chem. 246:6880-6885). The similarity of the amino acid sequences (FIG. 3) and the reactions catalyzed by these enzymes (FIG. 4) argue that the product of LCB1 is most likely SPT or a catalytic subunit of the enzyme, rather than a regulatory protein that regulates transcription of LCB1 or the enzymatic activity of SPT. 
     Besides lcb1-mutant strains, lcb2-mutant strains also lack SPT enzyme activity (Pinto, W. J., Wells, G. W., and Lester, R. L. 1992. J. Bateriol. 174:2575-2581). The LCB2 gene was isolated from a S. cerevisiae genomic DNA library of complementation for growth on medium lacking phytosphingosine of the lcb2 mutation carried in strain BS238. The strain was transformed with the same recombinant DNA library that was used for isolation of LCB1. Ura +  transformants were selected, pooled, and replated on plates lacking phytosphingosine to select transformants that could grow in the absence of phytosphingosine (Lcb + ). Plasmid DNA was recovered from Lcb +  cells by transformation into E. coli. Plasmid DNA isolated from E. coli was analyzed by restriction digestion. The pattern of restriction fragments indicated that all plasmids carried the same insert of about 7-kb which we designated B7 (FIG. 5). 
     LCB2 was localized by subcloning and testing the subclones for their ability to complement the lcb2 mutation in strain BS238 and allow the strain to grow in the absence of phytosphingosine (EXAMPLE 4). These data localized the LCB2 gene to a region near the ApaI site shown in FIG. 1. DNA around this site was sequenced and the sequence was scanned by computer in all reading frames. There was only one large open reading frame, indicated by the open box at the top of FIG. 5. The determined DNA sequence and the translated open reading frame representing the putative LCB2 protein are indicated in FIG. 6. 
     To prove that this open reading was the LCB2 gene we used the cloned gene to make a chromosomal deletion allele lcb2Δ3::URA3 (EXAMPLE 5), as shown in FIG. 5. The deletion allele was originally introduced into the diploid strain YPH501 and Southern blotting was used to verify that the deletion strain carried one normal allele and the deletion allele (data not shown). The diploid was sporulated and spores were tested for their Lcb phenotype. All 17 four-spored tetrads showed 2:2 segregation for the Lcb +  :Lcb -  phenotype and all the Lcb -  spores were Ura +  as expected for a URA3 gene disruption. Thus, the deleted region is needed for long-chain base synthesis as would be expected if the region was the LCB2 gene. To verify that the putative LCB2 gene indicated in FIG. 5 is allelic to the authentic LCB2 gene, we used the integrating vector pRSLCB2-2 (EXAMPLES 6 and FIG. 5) which only carries the 5&#39; half of the putative LCB2 gene. The plasmid was directed, by digestion with NaiI, to integrate into the genome of strain BS238 (relevant genotype lcb2), at the homologuos NsiI site located in the putative LCB2 gene. Integration at the correct chromosomal location was verified by Southern blotting (data not shown). The strain carrying the integrated plasmid was crossed to strain YPH-500, diploids were selected, and sporulated. Twenty-five four-spored tetrads gave 2 Lcb +  :2 Lcb -  segregation and all of the Lcb +  spores were Leu -  while the Lcb +  spores were Leu + . These data demonstrate that the cloned DNA fragment directs integration at or near the lcb2 allele carried in strain BS238. Taken as a whole the data demonstrate that the LCB2 gene has been cloned. 
     The predicted sequence of the LCB2 protein is shown in FIG. 6. The protein contains 561 amino acid residues. Since the amino terminus of the LCB2 protein has not been determined directly it is possible that the amino terminus of the actual protein is different than indicated in FIG. 6. The difference could occur either because of post-translational processing or because an ATG codon down stream of the one shown in FIG. 6 is used as the initiation codon. A membrane-associated helix is predicted for residues 57 to 77 (PYYISLLTYLNYLILIILGHV) and 443-463 (LGFIVYGVADSPVIPLLLYCP) by the algorithm of Eisenberg et al., (1984). 
     Comparison of the LCB2 protein sequence against other sequences in GenBank using the FASTA search procedure of Pearson, W. R. and Lipman, D. J., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:2444-2448 revealed that the sequence was homologous to the LCB1 protein and to various ALA synthases including the one from S. cerevisiae (FIG. 7). In addition, the sequence was homologuos to the BACBIOXWF (Genbank) and the ECOKBLTDH (Genbank, called EKBL (SEQ ID NO.: 8) in FIG. 3) sequences (data not shown). 
     The similarity of the LCB2 protein to the ALA synthases and to 2-amino-3-ketobutyrate CoA ligase (EKBL FIG. 3, ECOKBLTDH Gen Bank) seems particularly significant since these enzymes catalyze a reaction (FIG. 4) that is very similar to that catalyzed by SPT. In addition, the E. coli 2-amino-3-ketobutyrate CoA ligase uses pyridoxal phosphate as a cofactor (Mukherjee and Dekker, 1987) as do serine palmitoyltransferase and ALA synthase. The similarity of the amino acid sequences (FIG. 6) and the reactions catalyzed by these enzymes (FIG. 4) argue that the product of LCB2 is most likely SPT or a catalytic subunit of the enzyme, rather than a regulatory protein that regulates transcription of LCB2 or the enzymatic activity of SPT. 
     Potential uses of the LCB1 and LCB2 genes. 
     One use of the genes is to construct strains of S. cerevisiae or other organisms or cell lines that can be used to screen for inhibitors of SPT enzyme activity or inhibitors of expression of the LCB1 or LCB2 gene at the transcriptional or translational level. To construct a strain for screening inhibitors of SPT activity, one can use the LCB1 and LCB2 genes to overproduce their protein product. Overproduction will yield a host organism relatively more resistant to SPT inhibitors compared to a host that does not overproduce the proteins. This principle was first demonstrated in S. cerevisiae by Rine, J., Hansen, W., Hardeman, E., and Davis, R. W. 1983. Proc. Natl. Acad. Sci. U.S.A. 80:6750-6754. In the case of an inhibitor of transcription or translation, for example a triple helix-forming oligonucleotide or an antisense koligonucleotide, one can construct a strain carrying multiple copies of the LCB1 and LCB2 genes. Multiple copies should make the strain more resistant to the inhibitor than a strain having only one copy of each gene. A variation of this approach could be used for inhibitors of translation (an antisense oligonucleotide) in which the LCB1 and LCB2 coding regions would be fused to a strong promoter-enhancer region so that a single copy of the fusion genes would give high levels of LCB1 and LCB2 mRNA. 
     Another use of the LCB1 and LCB2 genes is to overexpress them and overproduce their protein product. Such overproduction usually makes it possible to purify the proteins. Expression and overproduction could be achieved in any number of organisms including E. coli, S. cerevisiae, or insect cells or other hosts for baculovirus vectors. The purified protein could then be used to identify or design inhibitors of SPT enzyme activity. 
     Finally, the LCB1 and LCB2 genes can be used to isolate their homologs from other organisms. Homologs can be isolated by complementation of the lcb1 and lcb2 mutation in appropriate S. cerevisiae host strains such as those presented in this application. Alternatively, degenerate primers for the polymerase chain reaction (PCR) could be designed based upon the sequence of LCB1 and LCB2 and used to prime a PCR reaction using genomic or cDNA from the organism whose LCB genes are to be cloned. LCB1 and LCB2 homologs from particular organisms would enable the design of highly specific triple-helix forming or antisense oligonucleotides or for inhibitors of SPT activity unique to a particular organism. 
     In the examples the following materials were used: 
     S. cerevisiae: The original lcb mutant MC6A (MATa lcb1-1 inol; Wells and Lester, 1983), was crossed with strain W303-1B (MATa ade2-1 can1-100 ura3-1 his3-11,15 trp1-1 leu2-3,112; obtained from R. J. Rothstein, Columbia, Univ.). Progeny from this cross were backcrossed to W303-1B and several offspring were selected for further study including strains X2A1B (MATa lcb1-1 ura3-1 trp1-1 his3-11,15) and 24D5 (MATα lcb1-1 ura3-1 trp1-1 leu2-3,112 his3-11,15). Strains YPH1(MATa ura3-52 lys2-801 ade2-101,), YPH500 (MATa ura3-52 leu2-801 amber  leu2-Δ101 ochre  trp1-Δ63 his3-Δ20 leu2-Δ1), and YPH501 (MATa/a ura3-52 leu2-801 amber  leu2-101 ochre  trp1-Δ63 his3Δ20 leu2-d1, were obtained from Sikorski, R. S. and Hieter, P., 1989, Genetics, 122:19-27. Strain BS238 (MATa lcb2 ura3-52 leu2-3,112 ade1) was from Pinto, W. J., Srinivasan, B., Shepherd, S., Schmidt, A., Dickson, R. C., and Lester, R. L. 1992. J. Bacteriol. 174:2565-2574. Strain SJ21R (MATa ura3-52 leu2-3,112 ade1 MEL1) was described in Dickson, R. C., Wells, G. B., Schmidt, A., and Lester, R. L. 1990. Mol. Cell. Biol. 10:2176-2181. The YPH strains are sensitive to the long-chain base phytosphingosine and in order to transform them with DNA it is necessary to use 12.5 μM phytosphingosine and 0.025% tergitol (half of the normal concentrations) in selection plates. Likewise, for genetic crosses involving YPH strains it is necessary to make the same adjustments for dissection plates (minimal medium, Sherman, F., Fink, G. R., and Hicks, T. B. 1986. Methods in Yeasts Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y.) otherwise spores will not germinate. 
     Escherichia coli: strain DH5a was used for propagation of plasmids. 
     Media: PYED contained 1% peptone, 1% yeast extract, 2% agar (for plates), 50 mM sodium succinate (pH 5), inositol (50 mg/l), potassium phosphate monobasic (50 mg/ml), and 2% or 4% glucose. Minimal medium contained 1× Difco Yeast Nitrogen Base without amino acids, 50 μM sodium succinate (pH 5), 2% glucose, 1.5% agar (for plates), inositol (50 mg/ml), valine (150 mg/ml), isoleucine (30 mg/ml), threonine (200 mg/ml) and these supplements at 20 mg/l: adenine sulfate, arginine-HCl, histidine-HCl, leucine, lysine-HCl, methionine, tryptophan, and uracil. One or more supplements were omitted from minimal medium for selection of yeast transformants. For strains requiring long chain base the medium was supplemented with 25 μM phytosphingosine (Sigma, St. Louis, Mo.). A 10× stock solution of phytosphingosine was prepared by adding 0.25 ml of 100 μM phytosphingosine (dissolved in 95% ethanol) to 99.75 ml of a 0.5% solution of tergitol (Sigma, St. Louis, Mo.). 
     DNA sequencing: Synthetic oligonucleotide primers were used for dideoxynucleotide sequencing with Sequenase Version 2.0 DNA Polymerase (USB, Cleveland, Ohio) essentially as recommended by the supplier. The LCB1 sequence (FIG. 2) has been deposited in the Gen Bank and given accession number M63674. The LCB2 sequence (FIG. 6) has been deposited in the Gen Bank and given accession number M95669. 
     Serine palmitoyltransferase activity assays were done as described in Buede, R., Rinker-Schaffer, C., Pinto, W. J., Lester, R. L., and Dickson, R. C. 1991. J. Bacteriol. 173:4325-4332. 
     Miscellaneous Procedures--Yeast were transformed by the lithium acetate procedure described by Sherman, F., Fink, G. R., and Hicks, T. B. 1986. Methods in Yeasts Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Genetic crosses and tetrad analysis were done by standard procedures (ibid). Southern blots were done essentially as described by Maniatis, T., Fritsch, E. F., and Sambrook, J. 1982. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. For Southern blots [ 32  P]dATP-labeled probes were prepared by the method of Feinberg, A. P., and Vogelstein, B. 1983. Anal. Biochem. 132:6-13. 
     EXAMPLE 1 
     The plasmid pLCB (FIG. 1) was isolated from a S. cerevisiae genomic DNA library carried in a vector containing the CEN3 region of S. cerevisiae DNA. The 6.44 kb vector was pBR322 with a 0.63 kb Sau3A CEN3 DNA fragment inserted into the PvuII site of the vector and a 1.4 kb TRP1ARS1 fragment inserted into the EcoRI site of the vector. These ligations were done with molecules whose ends were made blunt-ended so that the original restriction sites were destroyed. Sau3A genomic DNA fragments of 8 kb average size from strain X2180 (a/a gal2/gal2) were cloned into the BamHI site of the vector (the library was a gift from Zymogenetics, Seattle, Wash.). To construct YCp50-LCB1, a 4.7 kb StuI fragment from pLCB1 containing the LCB1 region, was subcloned into the NruI site of YCp50 (Rose, M. D. 1987. Meth. Enzymology. 152:481-504). 
     EXAMPLE 2 
     Strain SL1 as derived from strain SJ21R by replacement of the LCB1 allele with a mutant allele that was disrupted by inserting a 1.1 kb URA3 DNA fragment from S. cerevisiae into the SalI site of LCB1 (FIG. 1 shows the SalI site). The lcb1::URA3 -disrupted allele was prepared by ligating a 4.3 kb HindIII-StuI fragment, carrying LCB1, derived from pLCB (FIG. 1) to pTZ18 (Pharmacia) which had been cleaved with the restriction endonucleases HindIII and SmaI. The resulting plasmid, pTZ18-LCB1 (FIG. 1), was cleaved with SalI and ligated with a 1.1 kb URA3 DNA fragment having SalI cohesive ends to yield pTZ18-LCB1::URA3. To replace the LCB1 chromosomal allele with the URA3-disrupted allele, ten micrograms of pTZ18-LCB1::URA3 DNA was cleaved with XbaI and ClaI, extracted with phenol, phenol:chloroform and chloroform, and precipitated with ethanol. The DNA was transformed into strain SJ21R with selection for Ura +  transformants. Replacement of the LCB1 chromosomal allele with the URA3-disrupted allele was verified by Southern blot analysis. Total DNA isolated from SL1 and the non-disrupted parental strain SJ21R was cleaved with the restriction endonucleases NruI and StuI. Following Southern blot analysis, the parental strain showed a 4 kb band of hybridization, as expected, when the blot was probed with a  32  P-labeled NruI to StuI DNA probe containing the LCB1 region (FIG. 1). If the lcb1::URA3-disrupted allele had replaced the wild type allele of LCB1 in strain SL1 then the Southern blot of strain SL1 should show two bands that hybridize to the  32  P-probe because URA3 contains a StuI cleavage site. The fragments should be 2.1 kb and 3 kb in length. The Southern blot (data not shown) contained the two expected bands of hybridization indicating that strain SL1 carried the lcb1::URA3-disruption allele. 
     EXAMPLE 3 
     YIpLCB1-1was constructed by inserting TRP1 of S. cerevisiae, as a 1.4 kb Hind III fragment, into the Hind III site of pTZ18-LCB1. YIpLCB1-1 was cleaved at its unique BamHI site (FIG. 1), located on the 3&#39; side of LCB1, and the linear DNA was used to transform strain 24D5 with selection for Ura +  transformants. Integration at the expected chromosomal location was verified by southern blotting. Transformants were crossed to strain YPH1. 
     EXAMPLE 4 
     Plasmids carrying all of or portions of LCB2 (FIG. 2) were constructed using standard molecular cloning techniques as follows. Insert B7 is a 7 kb BamHI S. cerevisiae DNA fragment cloned into the BamHI site of pRS315 (Sikorski and Hieter, 1989). Insert B7ΔS is a 4.9 kb BamHI-SalI fragment cloned into pRS315 at the BamHI-SalI sites of the polylinker. Insert 2.3 is a 2.3 kb BamHI-SacI fragment cloned into pRS316 (Sikorski and Hieter, 1989) at the BamHI-SacI sites of the polylinker. Insert LCB2-R is a 4.3-kb EcoRI fragment made blunt-ended by filling in the ends with the Klenow fragment of DNA polymerase I and ligated into the SmaI site of pRS315. 
     EXAMPLE 5 
     S. cerevisiae strain LCB25, carrying the lcb2Δ3::URA3 allele (FIG. 5), was derived from strain YPH501 as follows: The LCB2-R insert, carried in pIC20R, Marsh, J. L., Erfle, M. and Wykes, E. J., 1984, Gene 32:481-485, at the EcoRI site of the polylinker, was cleaved with the restriction endonucleases Clal and XbaI (FIG. 5), the ends of the molecules were made blunt by treatment with the Klenow fragment of DNA polymerase I, and the fragment was ligated to a 1.1 kb URA3 fragment having blunt ends to give the lcb2Δ3::URA3 allele (FIG. 5). 
     EXAMPLE 6 
     The integrating vector pRSLCB2-2 (FIG. 5) was constructed by cloning a 2.6-kb BamHI-ApaI fragment from the B7 insert into the BamHI-ApaI region of the polylinker in pRS305 (Sikorski and Hieter, 1989). pRS305 carries the LEU2 marker gene that was used for selection of transformants in S. cerevisiae strain BS238. 
     DETAILED DESCRIPTION OF THE FIGURES 
     FIG. 1 
     Structure of Plasmids. The plasmid pLCB carrying the LCB1 gene is shown. The approximate location of LCB1 is indicated. Not all restriction endonuclease sites are indicated in a given plasmid. The open arrowhead in pTZ18-LCB1 represents the T7 promoter. DNA sequences are: open box, S. cerevisiae; TRP1, a marker gene for selection in S cerevisiae; ARS1, a S. cerevisiae autonomous replication sequence; CEN3 a centromere for maintenance of a single-copy of the vector in yeast; BLA and TET confer ampicillin and tetracycline resistance in E. coli, respectively. Abbreviations for restriction endonucleases are: B, BamHl, C, ClaI: E, EcoRI; H, HindIII; Ha, HpaI; K, KpnI; P, PstI; S, SalI; Sa, Sau3A; Sac, SacI; Sm, SmaI; St, StuI; X, XbaI. 
     FIG. 2 
     DNA sequence of LCB1. The nucleotide sequence of the LCB1 gene of S. cervisiae is presented along with the deduced protein sequence of the 558 amino acids. The predicted translation start codon is indicated by +1. 
     FIG. 3 
     Comparison of the deduced amino acid sequence of LCB1 to other proteins. The protein sequences of LCB1 and the mouse (ALSM ((SEQ ID. NO.:10)), chicken (ALSC ((SEQ ID. NO.:11)), and yeast (ALSY ((SEQ ID. NO.:12)) 5-aminolevulinic acid synthases were compared using the procedure of Pearson and Lipman (1988) and aligned for maximum similarity. The 2-amino-3-ketobutyrate CoA ligase (EKBO ((SEQ ID. NO.:8)) and the biotin synthetase (EBIO ((SEQ ID. NO.:7)) sequences were identified and aligned by using the FASTA algorithm (ibid). Colons (:) represent identity between residues while dots (.) denote conservative replacements by similar residues. Insertions made during the alignment optimization process are indicated by dashes (--). 
     FIG. 4 
     Comparison of the reactions catalyzed by serine palmitoyltransferase, ALA synthase, and 2-amino-3ketobutyrate CoA ligase. 
     FIG. 5 
     Structure of Plasmids. A restriction map of the 7 kb BamHI fragment carrying the LCB2 gene is shown at the top of the figure and the approximate location of LCB2 and the direction of transcription are indicated. Not all of the cutting sites for a particular restriction endonuclease are indicated. A. Portions of the region carrying LCB2 were tested for their ability to complement the Lcb -  phenotype of an lcb2-defective strain. B. Structure of a deletion allele. C. Structure of the chromosomal insert carried in pRSLCB2-2. Vector sequences are not shown. Abbreviations for restriction endonucleases are: A, ApaI; B, BamHl; C, ClaI; E, EcoRI; Ns, NsiI; Sa, SalI; S, SacI; Sn, SnaBl; Sp, SspI; X, XbaI. 
     FIG. 6 
     DNA sequence of LCB2. The nucleotide sequence of the LCB2 gene of S. cervisiae is presented along with the deduced protein sequence of the 561 amino acids. Numbers on the right side of the figure indicate amino acid residues while numbers on the left indicate nucleotides. The A of the predicted ATG initiation codon has been designated as +1. 
     FIG. 7 
     Comparison of the predicted LCB1 ((SEQ ID. NO.:13) and LCB2 ((SEQ ID. NO.:14) protein sequences with each other (identical residues indicated by an asterisk above the sequence) and with the ALA synthase of S. cervisiae (HEM1$Yeast ((SEQ ID. NO.:15)). Asterisks below the sequence indicate amino acids that are identical in all three sequences while dots (.) indicate amino acids that are similar in the three sequences. Dashes (--) indicate gaps in the sequence introduced to improve alignment. 
     The invention now being fully described it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth therein. The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept and therefore such adaptations are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description only and not of limitation. 
     
         __________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 15(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 333(B) TYPE: Nucleic Acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polynucleotide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:CGCGTATTTTTTTTTTTTTGAGGCGCCATGATTTCTTACACGGTTTCTTTTTTTTTTCCT60TCTTTCCTTCTTGCTTCTCTGCTAACAAATTTTTCACTCATTCTTTTTTATAGGGGCATA120TTGCTGCGGTTAACTGTAGTGAACGAAAGTAAGATTGAGAAAATATAGTACTTAAGAAAA180AGAAAAGGAAAAATAAAAAAAATTCTTTTCAACATCATCGAGTAGCACAGTATAAGAGCG240CTCTAACCTTCTGCCTGGCCTCCAATATACACATTTTGCTCGTGTAGGGTTATTTATCCT300TTTTTCTTCCTTCCCACCCAAAAAAAAAAAGCA333(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1674(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:ATGGCACACATCCCAGAGGTTTTACCCAAATCAATACCGATTCCGGCA48METAlaHisIleProGluValLeuProLysSerIleProIleProAla51015TTTATTGTTACCACCTCATCGTACCTATGGTACTACTTCAATCTGGTG96PheIleValThrThrSerSerTyrLeuTrpTyrTyrPheAsnLeuVal202530TTGACTCAAATCCCGGGAGGCCAATTCATCGTTTCGTACATCAAGAAA144LeuThrGlnIleProGlyGlyGlnPheIleValSerTyrIleLysLys354045TCGCATCATGACGATCCATACAGGACCACGGTTGAGATAGGGCTTATT192SerHisHisAspAspProTyrArgThrThrValGluIleGlyLeuIle505560TTATACGGGATCATCTATTACTTGTCCAAGCCACAACAGAAAAAGAGT240LeuTyrGlyIleIleTyrTyrLeuSerLysProGlnGlnLysLysSer65707580CTTCAAGCACAGAAGCCCAACCTATCGCCCCAGGAGATTGACGCGCTA288LeuGlnAlaGlnLysProAsnLeuSerProGlnGluIleAspAlaLeu859095ATTGAGGACTGGGAGCCCGAGCCTCTAGTCGACCCTTCTGCCACCGAT336IleGluAspTrpGluProGluProLeuValAspProSerAlaThrAsp100105110GAGCAATCGTGGAGGGTGGCCAAAACACCCGTCACCATGGAAATGCCC384GluGlnSerTrpArgValAlaLysThrProValThrMETGluMETPro115120125ATTCAGAACCATATTACTATCACCAGAAACAACCTGCAGGAGAAGTAT432IleGlnAsnHisIleThrIleThrArgAsnAsnLeuGlnGluLysTyr130135140ACCAATGTTTTCAATTTGGCCTCGAACAACTTTTTGCAATTGTCCGCT480ThrAsnValPheAsnLeuAlaSerAsnAsnPheLeuGlnLeuSerAla145150155160ACGGAGCCCGTGAAAGAAGTGGTCAAGACCACTATCAAGAATTACGGT528ThrGluProValLysGluValValLysThrThrIleLysAsnTyrGly165170175GTGGGCGCCTGTGGTCCCGCCGGGTTCTACGGTAACCAGGACGTTCAT576ValGlyAlaCysGlyProAlaGlyPheTyrGlyAsnGlnAspValHis180185190TACACGTTGGAATATGATTTAGCACAGTTCTTTGGCACCCAAGGTTCC624TyrThrLeuGluTyrAspLeuAlaGlnPhePheGlyThrGlnGlySer195200205GTTCTGTACGGGCAAGACTTTTGTGCCGCACCCTCTGTTCTGCCTGCT672ValLeuTyrGlyGlnAspPheCysAlaAlaProSerValLeuProAla210215220TTCACAAAGCGTGGTGATGTTATCGTGGCAGACGACCAGGTGTCATTA720PheThrLysArgGlyAspValIleValAlaAspAspGlnValSerLeu225230235240CCAGTGCAAAATGCTCTGCAACTAAGCAGATCCACAGTCTACTACTTC768ProValGlnAsnAlaLeuGlnLeuSerArgSerThrValTyrTyrPhe245250255AACCACAACGATATGAATTCGCTAGAATGTTTATTAAACGAGTTGACC816AsnHisAsnAspMETAsnSerLeuGluCysLeuLeuAsnGluLeuThr260265270GAACAGGAGAAACTTGAGAAACTGCCCGCCATTCCAAGAAAATTTATC864GluGlnGluLysLeuGluLysLeuProAlaIleProArgLysPheIle275280285GTCACTGAGGGTATTTTCCACAACTCGGGCGATTTAGCTCCGTTGCCT912ValThrGluGlyIlePheHisAsnSerGlyAspLeuAlaProLeuPro290295300GAGTTGACTAAGCTGAAGAACAAGTACAAGTTCAGACTATTTGTTGAC960GluLeuThrLysLeuLysAsnLysTyrLysPheArgLeuPheValAsp305310315320GAAACCTTCTCCATTGGTGTTCTTGGCGCTACGGGCCGTGGGTTGTCA1008GluThrPheSerIleGlyValLeuGlyAlaThrGlyArgGlyLeuSer325330335GAGCACTTCAACATGGATCGCGCAACTGCCATTGACATTACCGTTGGG1056GluHisPheAsnMETAspArgAlaThrAlaIleAspIleThrValGly340345350TCCATGGCCACCGCGTTGGGGTCCACCGGTGGTTTTGTCCTGGGTGAC1104SerMETAlaThrAlaLeuGlySerThrGlyGlyPheValLeuGlyAsp355360365AGTGTTATGTGTTTGCACCAGCGTATTGGTTCCAATGCATATTGTTTT1152SerValMETCysLeuHisGlnArgIleGlySerAsnAlaTyrCysPhe370375380TCTGCCTGTTTGCCGGCTTACACCGTCACATCCGTCTCCAAAGTCTTG1200SerAlaCysLeuProAlaTyrThrValThrSerValSerLysValLeu385390395400AAATTGATGGACTCCAACAACGACGCCGTCCAGACGCTGCAAAAACTA1248LysLeuMETAspSerAsnAsnAspAlaValGlnThrLeuGlnLysLeu405410415TCCAAATCTTTGCATGATTCCTTTGCATCTGACGACTCCTTGCGTTCA1296SerLysSerLeuHisAspSerPheAlaSerAspAspSerLeuArgSer420425430TACGTAATCGTCACGTCCTCTCCAGTGTCTCCTGTCCTACATCTGCAA1344TyrValIleValThrSerSerProValSerProValLeuHisLeuGln435440445CTGACTCCCGCATATAGGTCTCGCAAGTTCGGATACACCTGCGAACAG1392LeuThrProAlaTyrArgSerArgLysPheGlyTyrThrCysGluGln450455460CTATTCGAAACCATGTCAGCTTTGCAAAAGAAGTCCCAGACAAACAAA1440LeuPheGluThrMETSerAlaLeuGlnLysLysSerGlnThrAsnLys465470475480TTCATTGAGCCATACGAAGAGGAGGAAAAATTTCTGCAGTCCATAGTA1488PheIleGluProTyrGluGluGluGluLysPheLeuGlnSerIleVal485490495GATCATGCTCTTATTAACTACAACGTTCTCATCACAAGAAACACTATT1536AspHisAlaLeuIleAsnTyrAsnValLeuIleThrArgAsnThrIle500505510GTTTTAAAACAGGAGACGCTACCAATTGTCCCTAGCTTGAAAATCTGC1584ValLeuLysGlnGluThrLeuProIleValProSerLeuLysIleCys515520525TGTAACGCCGCCATGTCCCCAGAGGAACTCAAAAATGCTTGCGAAAGT1632CysAsnAlaAlaMETSerProGluGluLeuLysAsnAlaCysGluSer530535540GTCAAGCAGTCCATCCTTGCCTGTTGCCAAGAATCTAATAAA1674ValLysGlnSerIleLeuAlaCysCysGlnGluSerAsnLys545550555(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 463(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polynucleotide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:TAAAAATAGAAAGCCAGTATATGCACACGCACATATATATATAAATATTTATACAATAAT60ACAAATAATCGTAACATCATCTCTGTCAAATTGACGTGGTGCACGGCGCCCAGAGAATGC120GCTAAAAATTTTCGGATCCGAAATTTTCTTTCCTTTTACCATCGAGGCAAAGCAACCTGT180ATTATTTATTTGTTTATTTATTAATAGAAAAGAAAGGAGTACTTTCGTGGTACGCTTTCT240TGAGCATTTTCGGTTTCACTAGGCAGAGAACTAACACAAGAGACACAGCAAACATCAAAC300AAGGTTAAAACAGCACACCAAGGCAATATGATGCATTTTAGAAAGAAATCCAGTATCAGT360AACACGAGTGATCATGACGGAGCGAACCGTGCCTCAGATGTCAAGATTTCTGAAGATGAC420AAGGCAAGATTGAAGATGCGTACTGCTTCCGTTGCTGATCCTA463(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 884(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polynucleotide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:GCAAATATTGATTCTCGATGAGGCATTTTCTGGAATGGAGGTAGAACCTATGATGCGTTG60TCATGAATTTTTAGAGGAGTGGCCTGGAACAGTCCTTGTAGTGGCACACGTTGCCGAAGA120GACACCAAAATGTGCCCATTACTTAAGGCTCATATCTCCTGGAGAGTATGAAATAGGCGA180TATGGAAAATTAAAGTTTTCTGTTGTGTGGCAGCAAGAGACAGAACCTCGATAATTTGAC240ATACGTATATAATAGTACATGTACATAAAAACGTACGCAAATATCGTATATCTGTTATAC300TACAAAACAATTACTTCTATATCATAGCCAGTTAGCGGGAACGACTTCAGCTAAATGGAC360TATCCATGCTTTAGGCAGAGGCGAAGCGCGGTGATTGGGTGTAACATCATCTCCTTTTCT420CTACGACAAATTCCCAAAAAAAAAATTTATGCTATGTTAATACCTGCACAATTCAACCGT480GCTGAAACGTAAAATTAAGGTGATTATACGGATAGTATACGATATTATCAATCTCATAAG540AAAAATCTCTTTTGAATTTAACGGAGGGATTATTCATTAGAAAGCGTTCTTACCATTCAC600TAGGAGCGAATCCGTGGAAGGTGTTTTAACGTTGCCACGAAAAACAGCTCTACATCGAAA660TAAAAGACAACAATCAGTGCCCGTAAGTTTCATTACTATTTTCTATTATTATCTGCAACT720TTTTATTAGTTAGGTTTTTTTTGTTTGTTTGTTTGTTTTCAATTGATTAATTTACAAGAC780AAAGAACCTTATATTTCGTGTTTTTCATTCTAAAGGAAAAAAAGCATAAAGAAGATTCCA840CACACTTTATTGTGATAGTTTTCAAAGTAAAAAGTAATAGATTA884(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1683(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:TGAGTACTCCTGCAAACTATACCCGTGTGCCCCTGTGCGAACCAGAGG48MetSerThrProAlaAsnTyrThrArgValProLeuCysGluProGlu51015AGCTGCCAGACGACATACAAAAAGAAAATGAATATGGTACACTAGATT96GluLeuProAspAspIleGlnLysGluAsnGluTyrGlyThrLeuAsp202530CTCCGGGGCATTTGTATCAAGTCAAGTCACGTCATGGGAAGCCACTAC144SerProGlyHisLeuTyrGlnValLysSerArgHisGlyLysProLeu354045CTGAGCCCGTTGTCGACACCCCTCCTTATTACATTTCTTTGTTAACAT192ProGluProValValAspThrProProTyrTyrIleSerLeuLeuThr505560ATCTAAATTATTTGATTCTGATTATATTAGGTCATGTTCACGACTTCT240TyrLeuAsnTryLeuIleLeuIleIleLeuGlyHisValHisAspPhe65707580TAGGTATGACCTTCCAAAAAAACAAACATCTGGATCTTTTAGAGCATG288LeuGlyMetThrPheGlnLysAsnLysHisLeuAspLeuLeuGluHis859095ATGGGTTAGCACCTTGGTTTTCAAATTTCGAGAGTTTTTATGTCAGGA336AspGlyLeuAlaProTrpPheSerAsnPheGluSerPheTyrValArg100105110GAATTAAAATGAGAATTGATGATTGCTTTTCTAGACCAACTACTGGTG384ArgIleLysMetArgIleAspAspCysPheSerArgProThrThrGly115120125TTCCTGGTAGATTTATTCGTTGTATTGATAGAATTTCTCATAATATAA432ValProGlyArgPheIleArgCysIleAspArgIleSerHisAsnIle130135140ATGAGTATTTTACCTACTCAGGCGCAGTGTATCCATGCATGAACTTAT480AsnGluTyrPheThrTyrSerGlyAlaValTyrProCysMetAsnLeu145150155160CATCATATAACTATTTAGGCTTCGCACAAAGTAAGGGTCAATGTACCG528SerSerTyrAsnTyrLeuGlyPheAlaGlnSerLysGlyGlnCysThr165170175ATGCCGCCTTGGAATCTGTCGATAAATATTCTATTCAATCTGGTGGTC576AspAlaAlaLeuGluSerValAspLysTyrSerIleGlnSerGlyGly180185190CAAGAGCTCAAATCGGTACCACAGATTTGCACATTAAAGCAGAGAAAT624ProArgAlaGlnIleGlyThrThrAspLeuHisIleLysAlaGluLys195200205TAGTTGCTAGATTTATCGGTAAGGAGGATGCCCTCGTTTTTTCGATGG672LeuValAlaArgPheIleGlyLysGluAspAlaLeyValPheSerMet210215220GTTATGGTACAAATGCAAACTTGTTCAACGCTTTCCTCGATAAAAAGT720GlyTyrGlyThrAsnAlaAsnLeuPheAsnAlaPheLeuAspLysLys225230235240GTTTAGTTATCTCTGACGAATTGAACCACACCTCTATTAGAACAGGTG768CysLeuValIleSerAspGluLeuAsnHisThrSerIleArgThrGly245250255TTAGGCTTTCTGGTGCTGCTGTGCGAACTTTCAAGCATGGTGATATGG816ValArgLeuSerGlyAlaAlaValArgThrPheLysHisGlyAspMet260265270TGGGTTTAGAAAAGCTTATCAGAGAACAGATAGTACTTGGTCAACCAA864ValGlyLeuGluLysLeuIleArgGluGlnIleValLeuGlyGlnPro275280285AAACAAATCGTCCATGGAAGAAAATTTTAATTTGCGCAGAAGGGTTGT912LysThrAsnArgProTrpLysLysIleLeuIleCysAlaGluGlyLeu290295300TTTCCATGGAAGGTACTTTGTGTAACTTGCCAAAATTGGTTGAATTGA960PheSerMetGluGlyThrLeuCysAsnLeuProLysLeuValGluLeu305310315320AGAAGAAATATAAATGTTACTTGTTTATCGATGAAGCCCATTCTATAG1008LysLysLysTyrLysCysTyrLeuPheIleAspGluAlaHisSerIle325330335GCGCTATGGGCCCAACTGGTCGCGGTGTTTGTGAAATATTTGGCGTTG1056GlyAlaMetGlyProThrGlyArgGlyValCysGluIlePheGlyVal340345350ATCCCAAGGACGTCGACATTCTAATGGGTACTTTCACTAAGTCGTTTG1104AspProLysAspValAspIleLeuMetGlyThrPheThrLysSerPhe355360365GTGCTGCTGGTGGTTACATTGCTGCTGATCAATGGATTATCGATAGAC1152GlyAlaAlaGlyGlyTyrIleAlaAlaAspGlnTrpIleIleAspArg370375380TGAGGTTGGATTTAACCACTGTGAGTTATAGTGAGTCAATGCCGGCTC1200LeuArgLeuAspLeuThrThrValSerTyrSerGluSerMetProAla385390395400CTGTTTTAGCTCAAACTATTTCCTCATTACAAACCATTAGTGGTGAAA1248ProValLeuAlaGlnThrIleSerSerLeuGlnThrIleSerGlyGlu405410415TATGTCCCGGACAAGGTACTGAAAGATTGCAACGTATAGCCTTTAATT1296IleCysProGlyGlnGlyThrGluArgLeuGlnArgIleAlaPheAsn420425430CCCGTTATCTACGTTTAGCTTTGCAAAGGTTAGGATTTATTGTCTACG1344SerArgTyrLeuArgLeuAlaLeuGlnArgLeuGlyPheIleValTyr435440445GTGTGGCTGACTCACCAGTTATTCCCTTACTACTGTATTGTCCCTCAA1392GluValAlaAspSerProValIleProLeuLeuLeuTyrCysProSer450455460AGATGCCCGCATTTTCGAGAATGATGTTACAAAGACGGATTGCTGTTG1440LysMetProAlaPheSerArgMetMetLeuGlnArgArgIleAlaVal465470475480TTGTTGTTGCTTATCCTGCTACTCCGCTGATCGAATCAAGAGTAAGAT1488ValValValAlaTyrProAlaThrProLeuIleGluSerArgValArg485490495TCTGTATGTCTGCATCTTTAACAAAGGAAGATATCGATTATTTACTGC1536PheCysMetSerAlaSerLeuThrLysGluAspIleAspTyrLeuLeu500505510GTCATGTTAGTGAAGTTGGTGACAAATTGAATTTGAAATCAAATTCCG1584ArgHisValSerGluValGlyAspLysLeuAsnLeuLysSerAsnSer515520525GCAAATCCAGTTACGACGGTAAACGTCAAAGATGGGACATCGAGGAAG1632GlyLysSerSerTyrAspGlyLysArgGlnArgTrpAspIleGluGlu530535540TTATCAGGAGAACACCTGAAGATTGTAAGGACGACAAGTATTTTGTTA1680ValIleArgArgThrProGluAspCysLysAspAspLysTyrPheVal545550555560ATT1683Asn(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 313(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polynucleotide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:GAATTTTACCTAATTGCTAGTTAGGTGAAAAATTACAAAATTTCTGGAAGACGTTGGAAA60CACGCAACGTCTTTTTGACATAAACTTAAAACTGCCAAAAGTCAAACAAAAATTGCAAAA120AAAGTAAAAAAAGTTACGAAAAAAAAAACATTTAAAAGAAAGAAGAAGTTAAAAGTGCAC180GCAATATGTTCCAGGATATGAAATGAAATACCTTTTGTTTCACCTTTTAAATAATTTAAT240GTTATATATACAACTTTATCGTATCATATTCGCAATTACATTATACAAGAATGAGTTTTT300TTTCGCGACAAAG313(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 49(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:GlnMetValValThrGluGlyValPheSerMetAspGlyAspSerAla51015ProLeuAlaGluIleGlnGlnValThrGlnGlnHisAsnGlyTrpLeu202530MetValAspAspAlaHisGlyThrGlyValIleGlyGluGlnGlyArg354045Gly(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 132(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:PheIleCysGlyThrGlnAspSerHisLysGluLeuGluGlnLysLeu51015AlaAlaPheLeuGlyMetGluAspAlaIleLeuTyrSerSerCysPhe202530AspAlaAsnGlyGlyLeuPheGluThrLeuLeuGlyXaaXaaAlaGlu354045AspAlaIleIleSerAspAlaLeuAsnHisAlaSerIleIleAspGly505560ValArgLeuCysLysAlaLysArgTyrArgTyrAlaAsnAsnAspMet65707580GlnGluLeuGluAlaArgLeuLysGluAlaArgGluArgGluXaaXaa859095XaaXaaXaaXaaAlaArgHisXaaValLeuIleAlaThrAspGlyLeu100105110PheSerMetAspGlyValIleAlaAsnLeuLysGlyValCysAspLeu115120125AlaAspLysTyr130(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 287(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:LeuAlaSerAsnAsnPheLeuGlnLeuSerAlaThrGluProValLys51015GluValValLysThrThrIleLysAsnTyrGlyValGlyAlaCysGly202530ProAlaGlyPheTyrGlyAsnGlnAspValHisTyrThrLeuGluTyr354045AspLeuAlaGlnPhePheGlyThrGlnGlySerValLeuTyrGlyGln505560AspPheCysAlaAlaProSerValLeuProAlaPheThrLysXaaXaa65707580ArgGlyAspValIleValAlaAspAspGlnValSerLeuProValGln859095AsnAlaLeuGlnLeuSerArgSerThrValTyrTyrPheAsnHisAsn100105110AspMetAsnSerLeuGluCysLeuLeuAsnGluLeuThrGluGlnGlu115120125LysLeuGluLysLeuProAlaIleProArgLysPheIleValThrGlu130135140GlyIlePheHisAsnSerGlyAspLeuAlaProLeuProGluLeuThr145150155160LysLeuLysAsnLysTyrLysPheArgLeuPheValAspGluThrPhe165170175SerIleGlyValLeuGlyAlaThrGlyArgGlyLeuXaaXaaXaaXaa180185190XaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaa195200205XaaXaaSerGluHisXaaXaaPheAsnMetAspArgAlaThrAlaIle210215220AspIleThrValGlySerMetAlaThrAlaLeuGlySerThrGlyGly225230235240PheValLeuGlyAspSerValMetCysLeuHisGlnArgIleGlySer245250255AsnAlaTyrCysPheSerAlaCysLeuProAlaTyrThrValThrSer260265270ValSerLysValLeuLysLeuMetAspSerAsnAsnAspAlaVal275280285(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 287(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:TrpCysSerAsnAspTyrLeuGlyIleSerArgHisProArgValLeu51015GlnAlaIleGluGluThrLeuLysAsnHisGlyAlaGlyAlaGlyGly202530ThrArgAsnIleSerGlyThrSerLysPheHisValGluLeuGluGln354045GluLeuAlaGluLeuHisGlnLysAspSerAlaLeuLeuPheSerSer505560CysPheValAlaAsnAspSerThrLeuPheThrLeuAlaLysLeuLeu65707580ProGlyCysGluIleTyrSerAspAlaGlyAsnHisAlaSerMetIle859095GlnGlyIleArgAsnSerGlyAlaAlaLysPheValPheArgHisAsn100105110AspProGlyHisLeuLysLysLeuLeuXaaXaaXaaXaaXaaXaaXaa115120125XaaXaaGluLysSerAspProLysThrProLysIleValAlaPheGlu130135140ThrValHisSerMetAspGlyAlaIleCysProLeuGluGluLeuCys145150155160AspValAlaHisGlnTyrGlyAlaLeuThrPheValAspGluValHis165170175AlaValGlyLeuTyrGlyAlaArgGlyAlaGlyIleXaaXaaXaaXaa180185190XaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaa195200205XaaXaaGlyGluArgXaaXaaXaaXaaAspGlyIleMetHisLysLeu210215220AspIleIleSerGlyThrLeuGlyLysAlaPheGlyCysValGlyGly225230235240TyrIleAlaSerThrArgAspLeuValAspMetValArgSerTyrAla245250255AlaGlyPheIlePheThrThrSerLeuProProMetMetLeuSerGly260265270AlaLeuGluSerValArgLeuLeuLysGlyGluGluGlyGlnAla275280285(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 287(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:TrpCysSerAsnAspTyrLeuGlyMetSerArgHisProArgValCys51015GlyAlaValMetAspThrLysLeuGlnHisGlyAlaGlyAlaGlyGly202530ThrArgAsnIleSerGlyThrSerLysPheHisValAspLeuGluLys354045GluLeuAlaAspLeuHisGlyLysAspAlaAlaLeuLeuPheSerSer505560CysPheValAlaAsnAspSerThrLeuPheThrLeuAlaLysMetLeu65707580ProGlyCysGlnIleTyrSerAspSerGlyAsnHisAlaSerMetIle859095GlnGlyIleArgAsnSerArgValProLysHisIlePheArgHisAsn100105110AspValAsnHisLeuArgGluLeuLeuXaaXaaXaaXaaXaaXaaXaa115120125XaaXaaLysLysSerAspProSerThrProLysIleValAlaPheGlu130135140ThrValHisSerMetAspGlyAlaValCysProLeuGluGluLeuCys145150155160AspValAlaHisGluHisGlyAlaIleThrPheValAspGluValHis165170175AlaValGlyLeuTyrGlyAlaArgGlyGlyGlyIleXaaXaaXaaXaa180185190XaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaa195200205XaaXaaGlyAspArgXaaXaaXaaXaaAspGlyValMetHisLysMet210215220AspIleIleSerGlyThrLeuGlyLysAlaPheAlaCysValGlyGly225230235240TyrIleSerSerThrSerAlaLeuIleAspThrValArgSerTyrAla245250255AlaGlyPheIlePheThrThrSerLeuProProMetLeuLeuAlaGly260265270AlaLeuGluSerValArgThrLeuLysSerAlaGluGlyGlnVal275280285(2) INFORMATION FOR SEQ ID NO:12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 287(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:TrpCysSerAsnLysTyrLeuAlaLeuSerLysHisProGluValLeu51015AspAlaMetHisLysThrIleAspLysTyrGlyCysGlyAlaGlyGly202530ThrArgAsnIleAlaGlyHisAsnIleProThrLeuAsnLeuGluAla354045GluLeuAlaThrLeuHisLysLysGluGlyAlaLeuValPheSerSer505560CysTyrValAlaAsnAspAlaValLeuSerLeuLeuGlyGlnLysMet65707580LysAspLeuValIlePheSerAspGluLeuAsnHisAlaSerMetIle859095ValGlyIleLysHisAlaAsnValLysLysHisIlePheLysHisAsn100105110AspLeuAsnGluLeuGluGlnLeuLeuXaaXaaXaaXaaXaaXaaXaa115120125XaaXaaGlnSerTyrProLysSerValProLysLeuIleAlaPheGlu130135140SerValTyrSerMetAlaGlySerValAlaAspIleGluLysIleCys145150155160AspLeuAlaAspLysTyrGlyAlaLeuThrPheLeuAspGluValHis165170175AlaValGlyLeuTyrGlyProHisGlyAlaGlyValAlaGluHisCys180185190AspPheGluSerHisArgAlaSerGlyIleAlaThrProLysThrAsn195200205AspLysGlyGlyAlaXaaXaaXaaXaaLysThrValMetAspArgVal210215220AspMetIleThrGlyThrLeuGlyLysSerPheGlySerValGlyGly225230235240TyrGlyAlaAlaSerArgLysLeuIleAspTrpPheArgSerPheAla245250255ProGlyPheIlePheThrThrThrLeuProProSerValMetAlaGly260265270AlaThrAlaAlaIleArgTyrGlnArgCysHisIleAspLeuArg275280285(2) INFORMATION FOR SEQ ID NO:13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 625(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:MetAlaHisIleProGluXaaXaaXaaXaaValLeuProLysSerIle51015ProIleProAlaPheIleValThrThrSerSerTyrLeuTrpTyrTyr202530PheAsnLeuValLeuThrGlnIleProGlyGlyGlnPheIleValSer354045TyrIleLysLysSerHisHisAspAspProTyrArgThrThrValGlu505560XaaXaaXaaXaaXaaXaaIleGlyLeuIleLeuTyrGlyXaaXaaXaa65707580IleIleTyrTyrLeuSerLysProGlnGlnLysLysSerLeuGlnAla859095GlnLysProAsnXaaXaaXaaXaaLeuSerProGlnGluIleAspAla100105110LeuIleGluAspTrpGluProGluProLeuValAspProSerAlaThr115120125AspGluGlnSerTrpArgValAlaLysThrProValThrMetGluMet130135140ProIleXaaGlnAsnHisIleThrIleThrArgAsnAsnLeuGlnGlu145150155160LysTyrThrXaaXaaXaaAsnValPheXaaXaaXaaAsnLeuAlaSer165170175AsnAsnPheLeuGlnLeuSerAlaThrGluXaaProValLysGluVal180185190ValLysThrThrIleLysAsnTyrGlyValGlyAlaCysGlyProAla195200205GlyPheTyrGlyAsnGlnAspValHisTyrThrLeuGluTyrAspLeu210215220AlaGlnPhePheGlyThrGlnGlySerValLeuTyrGlyGlnAspPhe225230235240CysAlaAlaProSerValLeuProAlaPheThrLysArgXaaGlyAsp245250255ValIleValXaaAlaAspAspGlnValSerLeuProValGlnAsnAla260265270LeuGlnLeuSerArgSerThrValTyrTyrPheAsnHisAsnAspMet275280285AsnSerLeuGluCysLeuLeuAsnGluLeuThrGluGlnGluLysLeu290295300GluLysLeuProAlaIleProArgLysPheIleValThrGluGlyIle305310315320PheHisAsnSerGlyAspLeuAlaProLeuProGluLeuThrLysLeu325330335LysAsnLysTyrLysPheArgLeuPheValAspGluThrPheSerIle340345350GlyValLeuGlyAlaThrGlyArgGlyLeuSerGluHisXaaXaaPhe355360365AsnMetAspArgAlaThrAlaIleXaaXaaXaaXaaXaaXaaXaaXaa370375380XaaXaaXaaXaaXaaXaaXaaXaaXaaXaaAspIleThrValGlySer385390395400MetAlaThrAlaLeuGlySerThrGlyGlyPheValLeuGlyAspSer405410415ValMetCysLeuHisGlnArgIleGlySerAsnAlaTyrCysPheSer420425430AlaCysLeuProAlaTyrThrValThrSerValSerLysValLeuLys435440445LeuMetAspSerAsnAsnAspAlaValGlnThrLeuGlnLysLeuSer450455460LysXaaSerLeuHisAspSerPheAlaSerAspAspSerLeuArgSer465470475480TyrValIleValThrSerSerProValSerProValLeuHisLeuGln485490495LeuThrProAlaTyrArgSerArgLysPheGlyXaaXaaXaaXaaXaa500505510XaaXaaXaaXaaTyrThrCysGluGlnLeuPheGluThrMetSerAla515520525LeuGlnLysLysSerGlnThrAsnLysPheIleGluProTyrGluGlu530535540GluGluLysPheLeuGlnSerIleValAspHisAlaLeuIleAsnTyr545550555560AsnValLeuIleThrArgAsnXaaXaaXaaXaaThrIleValLeuLys565570575GlnGluThrLeuProIleValProSerLeuLysIleCysCysAsnAla580585590AlaMetSerProGluGluLeuLysAsnAlaXaaXaaXaaCysGluSer595600605ValLysGlnSerIleLeuAlaCysCysGlnGluSerAsnXaaXaaXaa610615620Lys625(2) INFORMATION FOR SEQ ID NO:14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 625(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:MetSerThrProAlaAsnTyrThrArgValProLeuCysGluProGlu51015GluLeuProAspAspIleGlnLysGluAsnGluTyrXaaXaaXaaXaa202530XaaXaaXaaGlyThrLeuAspSerProGlyHisLeuTyrGlnValXaa354045XaaXaaXaaLysSerArgHisGlyLysProLeuProGluProValVal505560AspThrProProTyrTyrIleSerLeuLeuThrTyrLeuAsnTyrLeu65707580IleLeuIleIleLeuGlyHisValHisAspPheLeuGlyMetThrPhe859095GlnLysAsnLysHisLeuAspLeuLeuGluHisAspGlyLeuAlaPro100105110TrpPheSerAsnPheGluSerPheTyrValArgArgIleLysMetArg115120125IleAspAspCysPheXaaXaaSerArgProThrThrGlyValProGly130135140ArgPheXaaIleArgCysIleAspArgIleSerHisAsnIleAsnGlu145150155160TyrPheThrTyrSerGlyAlaValTyrProCysMetAsnLeuSerSer165170175TyrAsnTyrLeuGlyPheAlaGlnSerLysGlyGlnCysThrAspAla180185190AlaLeuGluSerValAspLysTyrSerIleGlnSerGlyGlyProArg195200205AlaGlnIleGlyThrThrAspLeuHisIleLysAlaGluLysLeuVal210215220AlaArgPheIleGlyLysGluAspAlaLeuValPheSerMetGlyTyr225230235240GlyThrAsnAlaAsnLeuPheAsnAlaPheLeuAspLysXaaLysCys245250255LeuValIleXaaSerAspGluLeuAsnHisThrSerIleArgThrGly260265270ValArgLeuSerGlyAlaAlaValArgThrPheLysHisGlyAspMet275280285ValGlyLeuGluLysLeuIleArgGluGlnIleValLeuGlyGlnPro290295300LysThrAsnArgProTrpLysLysIleLeuIleCysAlaGluGlyLeu305310315320PheSerMetGluGlyThrLeuCysAsnLeuProLysLeuValGluLeu325330335LysLysLysTyrLysCysTyrLeuPheIleAspGluAlaHisSerIle340345350GlyAlaMetGlyProThrGlyArgGlyValCysGluIleXaaXaaPhe355360365GlyValAspXaaProLysAspValXaaXaaXaaXaaXaaXaaXaaXaa370375380XaaXaaXaaXaaXaaXaaXaaXaaXaaXaaAspIleLeuMetGlyThr385390395400PheThrLysSerPheGlyAlaAlaGlyGlyTyrIleAlaAlaAspGln405410415TrpIleIleAspArgLeuArgLeuAspLeuThrThrValSerTyrSer420425430GluSerMetProAlaProValLeuAlaGlnThrIleSerSerLeuGln435440445ThrIleSerGlyGluIleCysProGlyGlnGlyThrGluArgLeuGln450455460ArgIleAlaPheAsnSerArgTyrLeuArgLeuAlaLeuGlnArgLeu465470475480GlyPheIleValTyrGluValAlaAspSerProValIleProLeuLeu485490495LeuXaaXaaXaaTyrCysProSerLysMetXaaXaaXaaXaaXaaXaa500505510XaaXaaXaaXaaXaaXaaXaaXaaProAlaPheSerArgMetXaaMet515520525LeuGlnArgArgIleAlaValXaaXaaValValValAlaTyrProAla530535540ThrProXaaLeuIleGluSerArgValArgPheCysMetSerAlaXaa545550555560XaaSerLeuThrLysGluAspXaaXaaXaaXaaIleAspTyrLeuLeu565570575ArgHisValSerGluValGlyAspLysLeuAsnLeuLysSerAsnSer580585590GlyLysSerSerTyrAspGlyLysArgGlnArgTrpAspIleGluGlu595600605ValIleArgArgThrProGluAspCysLysAspAspLysTyrPheVal610615620Asn625(2) INFORMATION FOR SEQ ID NO:15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 625(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: polypeptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:MetGlnArgXaaSerIlePheAlaArgXaaXaaPheGlyAsnSerSer51015AlaAlaValSerThrLeuAsnArgXaaXaaXaaXaaXaaXaaXaaXaa202530XaaXaaXaaXaaLeuSerThrThrAlaAlaProHisAlaLysAsnGly354045TyrAlaThrAlaThrGlyAlaGlyAlaAlaAlaAlaThrAlaThrAla505560SerSerXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaaXaa65707580XaaXaaXaaXaaXaaThrHisAlaAlaAlaAlaAlaAlaAlaAlaAla859095AsnHisSerThrGlnGluSerGlyPheAspTyrGluGlyLeuIleAsp100105110XaaXaaSerGluLeuGlnXaaXaaXaaXaaXaaXaaXaaLysLysArg115120125LeuAspLysSerTyrArgTyrPheAsnAsnIleAsnArgLeuAlaLys130135140GluPheProLeuAlaHisArgGlnArgGluAlaAspLysValThrVal145150155160TrpXaaXaaXaaXaaXaaXaaXaaXaaXaaCysXaaXaaXaaXaaSer165170175AsnAspTyrLeuAlaLeuSerLysXaaHisProGlnValLeuAspAla180185190MetHisLysThrIleAspLysTyrGlyCysGlyAlaGlyGlyThrArg195200205AsnIleAlaGlyHisAsnIleProThrLeuAsnLeuGluAlaGluLeu210215220AlaThrLeuHisLysLysGluGlyAlaLeuValPheSerSerCysTyr225230235240ValAlaAsnAspAlaValLeuSerLeuLeuGlyGlnLysMetLysAsp245250255LeuValIlePheSerAspGluLeuAsnHisAlaSerMetIleValGly260265270IleLysHisAlaAsnValLysLysHisIlePheLysHisAsnAspLeu275280285AsnGluLeuGluGlnLeuLeuXaaXaaXaaXaaXaaXaaXaaXaaXaa290295300GlnSerTyrProLysSerValProLysLeuIleAlaPheGluSerVal305310315320TyrSerMetAlaGlySerValAlaAspIleGluLysIleCysAspLeu325330335AlaAspLysTyrGlyAlaLeuThrPheLeuAspGluValHisAlaVal340345350GlyLeuTyrGlyProHisGlyAlaGlyValAlaGluHisCysAspPhe355360365GluSerHisArgAlaSerGlyIleAlaThrProLysThrAsnAspLys370375380GlyGlyAlaLysThrValMetAspArgValAspMetIleThrGlyThr385390395400LeuGlyLysSerPheGlySerValGlyGlyTyrValAlaAlaSerArg405410415LysLeuIleAspTrpPheArgSerPheAlaProGlyPheIlePheThr420425430ThrThrLeuProProSerValMetAlaGlyAlaThrAlaAlaIleArg435440445TyrGlnArgCysHisIleAspLeuArgThrSerGlnGlnLysXaaXaa450455460XaaXaaXaaXaaHisThrMetTyrValLysLysAlaPheHisGluLeu465470475480GlyIleProValIleProAsnProXaaSerHisIleValProValLeu485490495IleGlyAsnAlaAspLeuAlaLysGlnAlaSerAspIleLeuIleAsn500505510LysHisGlnIleTyrValGlnAlaIleAsnPheProThrValAlaArg515520525GlyThrGluArgLeuArgIleThrProThrProGlyHisThrAsnAsp530535540LeuSerAspIleLeuIleAsnAlaValAspAspValPheAsnGluLeu545550555560GlnLeuProArgValArgAspTrpGluSerGlnGlyGlyLeuLeuGly565570575ValGlyGluSerGlyPheValGluGluSerAsnLeuTrpThrSerSer580585590GlnLeuSerLeuThrAsnAspAspLeuAsnProXaaXaaXaaXaaAsn595600605ValArgAspProIleValLysGlnLeuGluValSerSerGlyIleLys610615620Gln625__________________________________________________________________________